

Antonio Omuro

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9239997/publications.pdf>

Version: 2024-02-01

70
papers

10,821
citations

101543

36
h-index

106344

65
g-index

70
all docs

70
docs citations

70
times ranked

17152
citing authors

#	ARTICLE	IF	CITATIONS
1	Radiotherapy combined with nivolumab or temozolomide for newly diagnosed glioblastoma with unmethylated <i>MGMT</i> promoter: An international randomized phase III trial. <i>Neuro-Oncology</i> , 2023, 25, 123-134.	1.2	150
2	Nivolumab plus radiotherapy with or without temozolomide in newly diagnosed glioblastoma: Results from exploratory phase I cohorts of CheckMate 143. <i>Neuro-Oncology Advances</i> , 2022, 4, vdac025.	0.7	18
3	Using Adversarial Images to Assess the Robustness of Deep Learning Models Trained on Diagnostic Images in Oncology. <i>JCO Clinical Cancer Informatics</i> , 2022, 6, e2100170.	2.1	17
4	Machine Learning Applications for Differentiation of Glioma from Brain Metastasis—A Systematic Review. <i>Cancers</i> , 2022, 14, 1369.	3.7	10
5	Machine Learning in Differentiating Gliomas from Primary CNS Lymphomas: A Systematic Review, Reporting Quality, and Risk of Bias Assessment. <i>American Journal of Neuroradiology</i> , 2022, 43, 526-533.	2.4	7
6	Phase III trial of chemoradiotherapy with temozolomide plus nivolumab or placebo for newly diagnosed glioblastoma with methylated <i>MGMT</i> promoter. <i>Neuro-Oncology</i> , 2022, 24, 1935-1949.	1.2	165
7	A phase II study of dose-dense temozolomide and lapatinib for recurrent low-grade and anaplastic supratentorial, infratentorial, and spinal cord ependymoma. <i>Neuro-Oncology</i> , 2021, 23, 468-477.	1.2	28
8	Genetic characterization of an aggressive optic nerve pilocytic glioma. <i>Brain Tumor Pathology</i> , 2021, 38, 59-63.	1.7	4
9	Sporadic adamantinomatous craniopharyngioma with double-hit somatic APC mutations. <i>Neuro-Oncology Advances</i> , 2021, 3, vda124.	0.7	3
10	Comparison of radiomic feature aggregation methods for patients with multiple tumors. <i>Scientific Reports</i> , 2021, 11, 9758.	3.3	17
11	Editorial: Advances in neuro-oncology: stepping in the right direction. <i>Current Opinion in Neurology</i> , 2021, 34, 825-826.	3.6	0
12	Consolidation Therapy in Primary Central Nervous System Lymphoma. <i>Current Treatment Options in Oncology</i> , 2020, 21, 74.	3.0	6
13	Erdheim-Chester disease among neuroinflammatory syndromes: the case for precision medicine. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2020, 7, e686.	6.0	2
14	Effect of Nivolumab vs Bevacizumab in Patients With Recurrent Glioblastoma. <i>JAMA Oncology</i> , 2020, 6, 1003.	7.1	805
15	Cerebrospinal fluid circulating tumor cells as a quantifiable measurement of leptomeningeal metastases in patients with HER2 positive cancer. <i>Journal of Neuro-Oncology</i> , 2020, 148, 599-606.	2.9	50
16	Phase I clinical trial of temsirolimus and perifosine for recurrent glioblastoma. <i>Annals of Clinical and Translational Neurology</i> , 2020, 7, 429-436.	3.7	29
17	Emerging Meningioma Therapies I: Precision Medicine, Targeted Therapies, and Mutation-Specific Approaches. , 2020, , 217-226.		0
18	The Role of Medical Therapy for Meningiomas. , 2020, , 201-215.		0

#	ARTICLE	IF	CITATIONS
19	Longitudinal cognitive assessment in patients with primary CNS lymphoma treated with induction chemotherapy followed by reduced-dose whole-brain radiotherapy or autologous stem cell transplantation. <i>Journal of Neuro-Oncology</i> , 2019, 144, 553-562.	2.9	48
20	Genomic Correlates of Disease Progression and Treatment Response in Prospectively Characterized Gliomas. <i>Clinical Cancer Research</i> , 2019, 25, 5537-5547.	7.0	107
21	ATIM-47. NIVOLUMAB VS BEVACIZUMAB IN PATIENTS WITH RECURRENT GLIOBLASTOMA: EXPLORATORY ANALYSIS OF MGMT METHYLATION STATUS AND BASELINE CORTICOSTEROID USE. <i>Neuro-Oncology</i> , 2019, 21, vi12-vi12.	1.2	3
22	Imaging biomarkers for brain metastases: more than meets the eye. <i>Neuro-Oncology</i> , 2019, 21, 1493-1494.	1.2	1
23	Applications of artificial intelligence in neuro-oncology. <i>Current Opinion in Neurology</i> , 2019, 32, 850-856.	3.6	34
24	Tumor mutational load predicts survival after immunotherapy across multiple cancer types. <i>Nature Genetics</i> , 2019, 51, 202-206.	21.4	2,702
25	Residual Tumor Volume, Cell Volume Fraction, and Tumor Cell Kill During Fractionated Chemoradiation Therapy of Human Glioblastoma using Quantitative Sodium MR Imaging. <i>Clinical Cancer Research</i> , 2019, 25, 1226-1232.	7.0	26
26	Radiographic patterns of recurrence and pathologic correlation in malignant gliomas treated with bevacizumab. <i>CNS Oncology</i> , 2018, 7, 7-13.	3.0	3
27	Multicenter Phase IB Trial of Carboxyamidotriazole Orotate and Temozolomide for Recurrent and Newly Diagnosed Glioblastoma and Other Anaplastic Gliomas. <i>Journal of Clinical Oncology</i> , 2018, 36, 1702-1709.	1.6	39
28	Phase I trial of aflibercept (VEGF trap) with radiation therapy and concomitant and adjuvant temozolomide in patients with high-grade gliomas. <i>Journal of Neuro-Oncology</i> , 2017, 132, 181-188.	2.9	16
29	Multicenter phase II study of temozolomide and myeloablative chemotherapy with autologous stem cell transplant for newly diagnosed anaplastic oligodendroglioma. <i>Neuro-Oncology</i> , 2017, 19, 1380-1390.	1.2	35
30	Ibrutinib Unmasks Critical Role of Bruton Tyrosine Kinase in Primary CNS Lymphoma. <i>Cancer Discovery</i> , 2017, 7, 1018-1029.	9.4	302
31	Diagnostic Accuracy of T1-Weighted Dynamic Contrast-Enhanced MRI and DWI-ADC for Differentiation of Glioblastoma and Primary CNS Lymphoma. <i>American Journal of Neuroradiology</i> , 2017, 38, 485-491.	2.4	71
32	Cerebrospinal fluid circulating tumor cells: a novel tool to diagnose leptomeningeal metastases from epithelial tumors. <i>Neuro-Oncology</i> , 2017, 19, 1248-1254.	1.2	79
33	Multicenter, Phase 1, Dose Escalation Study of Hypofractionated Stereotactic Radiation Therapy With Bevacizumab for Recurrent Glioblastoma and Anaplastic Astrocytoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 99, 797-804.	0.8	40
34	Long-term survival in AIDS-related primary central nervous system lymphoma. <i>Neuro-Oncology</i> , 2017, 19, 99-108.	1.2	49
35	OncoKB: A Precision Oncology Knowledge Base. <i>JCO Precision Oncology</i> , 2017, 2017, 1-16.	3.0	1,266
36	Molecular and Clinical Effects of Notch Inhibition in Glioma Patients: A Phase 0/I Trial. <i>Clinical Cancer Research</i> , 2016, 22, 4786-4796.	7.0	95

#	ARTICLE	IF	CITATIONS
37	A prospective trial of dynamic contrast-enhanced MRI perfusion and fluorine-18 FDG PET-CT in differentiating brain tumor progression from radiation injury after cranial irradiation. <i>Neuro-Oncology</i> , 2016, 18, 873-880.	1.2	72
38	High-dose methotrexate-based chemotherapy as treatment for histiocytic sarcoma of the central nervous system. <i>Leukemia and Lymphoma</i> , 2016, 57, 1961-1964.	1.3	7
39	Methotrexate and temozolomide versus methotrexate, procarbazine, vincristine, and cytarabine for primary CNS lymphoma in an elderly population: an intergroup ANOCEF-GOELAMS randomised phase 2 trial. <i>Lancet Haematology</i> , 2015, 2, e251-e259.	4.6	164
40	R-MPV followed by high-dose chemotherapy with TBC and autologous stem-cell transplant for newly diagnosed primary CNS lymphoma. <i>Blood</i> , 2015, 125, 1403-1410.	1.4	267
41	Multicenter phase 2 study of patupilone for recurrent or progressive brain metastases from non-small cell lung cancer. <i>Cancer</i> , 2015, 121, 4165-4172.	4.1	15
42	Phase I dose-escalation study of the PI3K/mTOR inhibitor voxtalisib (SAR245409, XL765) plus temozolomide with or without radiotherapy in patients with high-grade glioma. <i>Neuro-Oncology</i> , 2015, 17, 1275-1283.	1.2	61
43	Clinical Reasoning: Worsening neurologic symptoms in a brain tumor patient. <i>Neurology</i> , 2015, 85, e57-e61.	1.1	16
44	Clinical course and progression-free survival of adult intracranial and spinal ependymoma patients. <i>Neuro-Oncology</i> , 2015, 17, 440-447.	1.2	102
45	Phase II trial of sunitinib for recurrent and progressive atypical and anaplastic meningioma. <i>Neuro-Oncology</i> , 2015, 17, 116-121.	1.2	207
46	Current Role of Anti-Angiogenic Strategies for Glioblastoma. <i>Current Treatment Options in Oncology</i> , 2014, 15, 551-566.	3.0	24
47	Transcriptional diversity of long-term glioblastoma survivors. <i>Neuro-Oncology</i> , 2014, 16, 1186-1195.	1.2	69
48	Methotrexate re-challenge for recurrent primary central nervous system lymphoma. <i>Journal of Neuro-Oncology</i> , 2014, 117, 161-165.	2.9	84
49	Phase II Study of Bevacizumab, Temozolomide, and Hypofractionated Stereotactic Radiotherapy for Newly Diagnosed Glioblastoma. <i>Clinical Cancer Research</i> , 2014, 20, 5023-5031.	7.0	89
50	Glioblastoma and Other Malignant Gliomas. <i>JAMA - Journal of the American Medical Association</i> , 2013, 310, 1842.	7.4	1,779
51	Rituximab, Methotrexate, Procarbazine, and Vincristine Followed by Consolidation Reduced-Dose Whole-Brain Radiotherapy and Cytarabine in Newly Diagnosed Primary CNS Lymphoma: Final Results and Long-Term Outcome. <i>Journal of Clinical Oncology</i> , 2013, 31, 3971-3979.	1.6	386
52	Primary leptomenigeal lymphoma. <i>Neurology</i> , 2013, 81, 1690-1696.	1.1	70
53	Rare cell capture technology for the diagnosis of leptomenigeal metastasis in solid tumors. <i>Neurology</i> , 2013, 80, 1598-1605.	1.1	95
54	Multicenter phase II study of rituximab and temozolomide in recurrent primary central nervous system lymphoma. <i>Leukemia and Lymphoma</i> , 2013, 54, 58-61.	1.3	65

#	ARTICLE	IF	CITATIONS
55	Histological Predictors of Outcome in Ependymoma are Dependent on Anatomic Site Within the Central Nervous System. <i>Brain Pathology</i> , 2013, 23, 584-594.	4.1	53
56	Phase II trial of continuous low-dose temozolomide for patients with recurrent malignant glioma. <i>Neuro-Oncology</i> , 2013, 15, 242-250.	1.2	83
57	Neurological Complications of Non-Hodgkin Lymphoma. , 2012, , 267-285.		1
58	Outcomes of the oldest patients with primary CNS lymphoma treated at Memorial Sloan-Kettering Cancer Center. <i>Neuro-Oncology</i> , 2012, 14, 1304-1311.	1.2	68
59	Chemotherapy-related magnetic resonance imaging abnormalities mimicking disease progression following intraventricular liposomal cytarabine and high dose methotrexate for neurolymphomatosis. <i>Leukemia and Lymphoma</i> , 2012, 53, 1620-1622.	1.3	3
60	Limited Overall Survival in Patients with Brain Metastases from Triple Negative Breast Cancer. <i>Breast Journal</i> , 2012, 18, 345-350.	1.0	29
61	Atypical and anaplastic meningiomas treated with bevacizumab. <i>Journal of Neuro-Oncology</i> , 2012, 109, 187-193.	2.9	155
62	A prognostic gene expression signature in infratentorial ependymoma. <i>Acta Neuropathologica</i> , 2012, 123, 727-738.	7.7	148
63	Prophylactic intrathecal chemotherapy in primary CNS lymphoma. <i>Journal of Neuro-Oncology</i> , 2012, 106, 143-146.	2.9	51
64	A phase II study of the Ras-MAPK signaling pathway inhibitor TLN-4601 in patients with glioblastoma at first progression. <i>Journal of Neuro-Oncology</i> , 2012, 107, 343-349.	2.9	41
65	Pharmacotherapy for Primary CNS Lymphoma. <i>CNS Drugs</i> , 2011, 25, 447-457.	5.9	7
66	Methotrexate area under the curve as a prognostic factor in primary central nervous system lymphoma treated with immunochemoradiotherapy. <i>Leukemia and Lymphoma</i> , 2011, 52, 1891-1897.	1.3	10
67	Primary central nervous system lymphoma. <i>Current Opinion in Neurology</i> , 2011, 24, 633-640.	3.6	14
68	Primary CNS lymphoma in patients younger than 60: can whole-brain radiotherapy be deferred?. <i>Journal of Neuro-Oncology</i> , 2011, 104, 323-330.	2.9	54
69	Intensive Chemotherapy Followed by Hematopoietic Stem-Cell Rescue for Refractory and Recurrent Primary CNS and Intraocular Lymphoma: Soci�t� Fran�saise de Greffe de Mo�lle Osseuse-Th�rapie Cellulaire. <i>Journal of Clinical Oncology</i> , 2008, 26, 2512-2518.	1.6	301
70	Identifying clinically applicable machine learning algorithms for glioma segmentation: recent advances and discoveries. <i>Neuro-Oncology Advances</i> , 0, , .	0.7	4